Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Randomized, Open Label Study Evaluating a Poly(ADP-ribose) Polymerase-1(PARP-1) Inhibitor, SAR240550 (BSI-201), Administered Twice Weekly or Weekly, in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer (mTNBC)

NCT01045304 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT01045304
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01045304 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Randomized, Open Label Study Evaluating a Poly(ADP-ribose) Polymerase-1(PARP-1) Inhibitor, SAR240550 (BSI-201), Administered Twice Weekly or Weekly, in Combination With Gemcitabine/Carboplatin, in Patients With Metastatic Triple Negative Breast Cancer (mTNBC)
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2010
Completion date
November 30, 2012
Enrollment
163 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, metastatic